Yuan Zhi
Stock Analyst at B. Riley Securities
(4.54)
# 1,034
Out of 4,581 analysts
129
Total ratings
41.9%
Success rate
21.2%
Average return
Main Sectors:
Stocks Rated by Yuan Zhi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LYEL Lyell Immunopharma | Initiated Coverage: Buy | $44 | $12.99 | +238.72% | 1 | Jul 22, 2026 | |
| LNTH Lantheus Holdings | Rated: Buy | $97 → $129 | $102.64 | +25.68% | 26 | Jul 9, 2026 | |
| WHWK Whitehawk Therapeutics | Initiated Coverage: Buy | $10 | $3.68 | +171.74% | 1 | Jun 25, 2026 | |
| TNGX Tango Therapeutics | Rated: Buy | $21 → $35 | $26.65 | +31.33% | 7 | Jun 9, 2026 | |
| HYPR Hyperfine | Rated: Buy | $1.6 → $2 | $0.9156 | +118.44% | 8 | May 13, 2026 | |
| RDNT RadNet | Rated: Buy | $87 → $83 | $63.22 | +31.29% | 6 | May 1, 2026 | |
| SRTA Strata Critical Medical | Initiated Coverage: Buy | $8 | $5.09 | +57.17% | 1 | Mar 25, 2026 | |
| CATX Perspective Therapeutics | Rated: Buy | $11 → $13 | $2.87 | +352.96% | 13 | Mar 18, 2026 | |
| FHTX Foghorn Therapeutics | Maintained: Buy | $10 | $5.13 | +94.93% | 2 | Dec 17, 2025 | |
| RADX Radiopharm Theranostics | Maintained: Buy | $13 → $16 | $3.31 | +383.38% | 6 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $22 → $29 | $16.79 | +72.72% | 9 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 | $4.95 | +21.21% | 2 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 → $3 | $0.37 | n/a | 3 | Oct 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $16 → $2 | $0.8665 | n/a | 13 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $19 → $15 | $15.17 | n/a | 14 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $79 | $28.93 | n/a | 12 | Feb 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $34 | $31.98 | n/a | 5 | Jan 9, 2023 |
Lyell Immunopharma
Jul 22, 2026
Initiated Coverage: Buy
Price Target: $44
Current: $12.99
Upside: +238.72%
Lantheus Holdings
Jul 9, 2026
Rated: Buy
Price Target: $97 → $129
Current: $102.64
Upside: +25.68%
Whitehawk Therapeutics
Jun 25, 2026
Initiated Coverage: Buy
Price Target: $10
Current: $3.68
Upside: +171.74%
Tango Therapeutics
Jun 9, 2026
Rated: Buy
Price Target: $21 → $35
Current: $26.65
Upside: +31.33%
Hyperfine
May 13, 2026
Rated: Buy
Price Target: $1.6 → $2
Current: $0.9156
Upside: +118.44%
RadNet
May 1, 2026
Rated: Buy
Price Target: $87 → $83
Current: $63.22
Upside: +31.29%
Strata Critical Medical
Mar 25, 2026
Initiated Coverage: Buy
Price Target: $8
Current: $5.09
Upside: +57.17%
Perspective Therapeutics
Mar 18, 2026
Rated: Buy
Price Target: $11 → $13
Current: $2.87
Upside: +352.96%
Foghorn Therapeutics
Dec 17, 2025
Maintained: Buy
Price Target: $10
Current: $5.13
Upside: +94.93%
Radiopharm Theranostics
Dec 16, 2025
Maintained: Buy
Price Target: $13 → $16
Current: $3.31
Upside: +383.38%
Oct 28, 2025
Maintained: Buy
Price Target: $22 → $29
Current: $16.79
Upside: +72.72%
Sep 5, 2025
Maintained: Buy
Price Target: $6
Current: $4.95
Upside: +21.21%
Oct 2, 2024
Reiterated: Buy
Price Target: $4 → $3
Current: $0.37
Upside: n/a
Aug 7, 2024
Downgraded: Hold
Price Target: $16 → $2
Current: $0.8665
Upside: n/a
Jul 30, 2024
Upgraded: Buy
Price Target: $19 → $15
Current: $15.17
Upside: n/a
Feb 7, 2024
Reiterated: Buy
Price Target: $79
Current: $28.93
Upside: n/a
Jan 9, 2023
Maintained: Buy
Price Target: $34
Current: $31.98
Upside: n/a